tiprankstipranks
Trending News
More News >

Kissei Partners with Reborna for Rare Disease Therapies

Kissei Partners with Reborna for Rare Disease Therapies

Kissei Pharmaceutical Co (JP:4547) has released an update.

Confident Investing Starts Here:

Kissei Pharmaceutical Co. has entered into a research collaboration with Reborna Biosciences to develop treatments for genetic rare diseases, using Reborna’s RNA-targeting technology. Kissei will handle development and commercialization, providing payments including milestones and royalties to Reborna. This partnership aims to leverage both companies’ strengths to address challenges in rare disease drug discovery.

For further insights into JP:4547 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App